Navigation Links
GeoVax Labs, Inc. Plans Public Offering
Date:3/1/2010

ATLANTA, March 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company, today announced that it intends to file a registration statement for the sale of $20.0 million or more of its common stock. The offering may also include shares to be sold by selling stockholders, although no arrangements have been made. The purpose of the offering would be to raise funds to enable the Company to develop its vaccines business.

The Company anticipates filing the registration statement some time after it has filed its Annual Report on Form 10-K for the year ended December 31, 2009.  The timing of the offering will be determined at a later date, depending on several factors, including market conditions and when the registration statement is eligible to be declared effective by the SEC.

This press release is being issued in accordance with Rule 135 of the Securities Act of 1933, as amended.  THIS PRESS RELEASE IS NEITHER AN OFFER TO SELL NOR A SOLICITATION OF OFFERS TO PURCHASE COMMON STOCK.  A REGISTRATION STATEMENT RELATING TO THE COMMON STOCK OF THE COMPANY HAS NOT YET BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.  THE OFFER, IF COMMENCED, WILL BE MADE ONLY BY THE PROSPECTUS TO BE INCLUDED IN THE REGISTRATION STATEMENT

Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether the SEC will declare the proposed registration statement to be effective and when, whether the Company will be able to sell its common stock on terms acceptable to it or at all, market conditions, and factors over which GeoVax has no control, including those described in the Company's most recent Annual Report on Form 10-K and its other SEC filings and reports. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so, unless otherwise required by law.

SOURCE GeoVax Labs, Inc.

Back to top

RELATED LINKS
http://www.geovax.com

'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
2. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
3. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
4. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
5. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
6. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
7. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. GeoVax Secures $10 Million Financing Commitment
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
11. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... -- Xynomic Pharmaceuticals, Inc., an oncology drug research and ... exclusive worldwide rights to develop, manufacture and commercialize ... hematological and solid tumors. To date ... clinical trials of Abexinostat in US, EU and ... completed, demonstrating that Abexinostat is clinically active in ...
(Date:2/23/2017)... 2017 LG Innotek hat heute die weltweit ... beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... 200 und 280 nm und eignet sich damit für Sterilisationsaufgaben. ... DNA zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung ... ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert Herjavec ... it’s not if you will be attacked, but when.” However, he and many others ... health care. , Improvements in auditing and monitoring have taken security in health care ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
(Date:2/24/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... Yisrayl makes an astounding statement when he says that the entire Bible was ... details the current times so plainly that anyone should be able to see the ...
(Date:2/24/2017)... Farifax, VA (PRWEB) , ... February 24, 2017 , ... ... winners for excellence in radiology marketing programs at the annual Building Better ... the Worthington Renaissance Fort Worth Hotel in Fort Worth, Texas. Nine awards are given ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, the ... Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, on ... donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch ...
Breaking Medicine News(10 mins):